Trial Profile

Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 18 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ciforadenant (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Renal cell carcinoma
Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
Sponsors Corvus Pharmaceuticals

Most Recent Events

17 Oct 2025 According to a Corvus Pharmaceuticals media release, interim data from this trial will be presented today in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2025, which is taking place October 17-21, 2025 in Berlin, Germany.
17 Oct 2025 Interim results presented in the Corvus pharmaceuticals media release.
25 Mar 2025 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com